DOCSLIB.ORG

Ibuprofen: a Simple Cost-Efficacy Com Parison for Dental Use

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ibuprofen: a Simple Cost-Efficacy Com Parison for Dental Use CLINICAL Ketorolac versus Ibuprofen: A Simple Cost-Efficacy Com parison for Dental Use i Ben Balevi, B. Eng., DDS As dentists, we are regularly for its analgesic qualities than for its On a fractional cost compari inundated with promo anti-inflammatory activity. Two son, Motrin (400 mg tablets) is 55 tional literature on the studies investigating the efficacy of per cent less expensive than ke newest dental therapies and prod a single dose of ketorolac (10 mg) torolac. Even better value is found ucts. For the most part, this com following dental impaction surgery with generic ibuprofen (400 mg mercial marketing consists of large, have demonstrated it to be a supe tablets) and OTC ibuprofen, with four-color, glossy spreads, which rior analgesic to the acetamino fractional costs of 41 per cent and typically summarize the efficacy of phen and codeine combination an 21 per cent respectively. Hence, a product in one or two lines (i.e., algesic Tylenol 3.67 The second the cost to the patient of a typical the slogan), complemented by study also included ibuprofen (400 post dental surgery prescription of convincing graphs and photo mg)as one of the treatment groups. ibuprofen is one-half to one-fifth graphs. These marketing methods This second study revealed thatthe the cost of ketorolac. can be impressive — the recent clinical efficacy of ketorolac (10 For ketorolac to be cost-effective, introduction of ketorolac (Toradol) mg)versus ibuprofen (400 mg)was its significantly higher cost would is a case in point. statistically insignificant.7 have to be concomitant with a Ketorolac is being aggressively There is no doubt that ketorolac proven analgesic advantage over marketed to dentists as a "non-nar is an effective analgesic. However, ibuprofen. Asdiscussed, a search of cotic" analgesic that provides "nar for pain incurred during dental ex the scientific literature to date does cotic efficacy without narcotic traction, ketorolac and ibuprofen not support the premise that ketoro drawbacks." At first glance, this have been shown, scientifically, to lac is superior to ibuprofen for den promotional strategy gives the im be equally potent analgesics. The tal use. Therefore, it seems reason pression that until ketorolac came question that begs to be asked, able to conclude that ketorolac is on the scene, there was no other then, is:are the two drugs available notably less cost effective than "non-narcotic" alternative for the to the patient at a comparable cost? ibuprofen for the routine manage management of acute dental pain. Table I compares the costs of ment of post dental extraction pain. This, however, is not the case. ketorolac (10 mg) with the costs of Ketorolac may well be a more Ibuprofen (e.g., Motrin, Advil, three available types of ibuprofen. potent analgesic than ibuprofen. and Mediprin) is also a "non-nar The comparison is based on the However, even if this is the case, cotic" analgesic with proven "nar cost to the patient of a typical post ketorolac's advantage is not real cotic efficacy," and it has been dental surgery prescription of 25 ized when it is used to control post used for managing moderate to pills for each drug. The OTC (over- dental extraction pain. In other moderately severe dental pain for the-counter) form of ibuprofen is words, as painful as dental surgery well over a decade. Ibuprofen is a only available in 200 mg tablets. may seem, it may not be painful NSAID (nonsteroidal anti-inflam Therefore, a box of 50 pills is con enough to take advantage of ke matory drug)with both anti-inflam sidered to be equivalent to 25 pills torolac's superior analgesic prop matory and analgesic properties.1 of 400 mg ibuprofen. Exceptforthe erties, if these properties actually Many studies have confirmed its cost of OTC ibuprofen, all other exist. efficacy for relieving post dental costs include the pharmacy's pro I do not wish to totally discount surgery pain.'"5 ketorolac's usefulness as a dental l.inuary/ fessional fees. As such, these costs Janvier Ketorolac is also classified as an will vary somewhat from city to city analgesic. On the contrary, the 1994 Vol. 60 NSAID, but it is considered more and province to province. drug is a welcome addition to our No. 1 31 analgesic armamentarium. For in Table I stance, ketorolac is available for Cost Comparison of Ketorolac and Ibuprofen intramuscular injection, and is the only true alternative to narcotics AnalgesicType Total Cost Cost per Dose Fractional via this route. A single intramuscu to Patient($)• (^Tablet)" Cosf lar injection (I.M.) dose of ketoro lac (30 mg) has been shown to be Ketorolac as effective as a 100 mg I.M. injec Toradci* 10mg (25 tablets) 2750 1.10 1.00 tion of meperidine (Demerol) for controlling post oral surgery Ibuprofen pain.89 Motrin9 400 mg (25 tablets) 15.00 0.60 0.55 On top of its I.M. advantage, ketorolac's oral tablet form could Generic 400mg(25tablets) 1125 0.45 0.41 be used as a back-up in those few OTC 200 mg3 (50 pills) 6.00 024 021 cases where patients do not re spond to the normally prescribed a. Costs given bya Toronto areapharmacy. These costs indude thepharmacy's professional fees. analgesics. However, ketorolac, as As such, thesespecific costs may vary from city todtyandprovince toprovince. well as other NSAIDs, including b.Calculated bydividing thetotal cost topatient by25pills. Theamount ofpills dispensed affects ibuprofen, should not be adminis this value. tered to patients presenting with a c.Calculated bydividing thecostofeachanalgesic bythecostofketorolac. Thevaluerepresents medical history of ASA allergy or thefractional costofeachanalgesic tothatofketorolac. serious gastrointestinal bleeding d. Over-the-counter (OTC) ibuprofen isonly available in200mg pills. Two pills ofOTC areequiva due to an underlying peptic ulcer lent toone Ibuprofen (400 mg) pill. Aboxof50OTC pills isequivalent todispensing 25Ibuprofen disease. (400 mg) pills. Nevertheless, at this time it is simply not cost effective to rou acetaminophen and acetaminophen- tinely prescribe ketorolac (oral) for Dr. Ben Balevi is affiliated with the Oril- codeine combination in postoperative acute post dental surgery pain. This lia Soldiers' Memorial Hospital and the oral surgery pain. Pharmacotherapy applies to all dental surgical proce Huronia Regional Centre. 10:94S-105, 1990. dures with the possible exception Reprint requests to: Dr. Ben Balevi. 605 8. Brown, C.R.The analgesic efficacyof of dental impaction surgery, as the Finch Ave. W. Suite 923, Toronto, ON ketorolac tromethamine by oral and in intensity of post surgical pain may M2R 1P1. tramuscular administration in single- be significantly higher in these dose studies on various postoperative cases. As such, more research is pain states. Paper delivered at the fifth World Congress on Pain. Hamburg, needed on ketorolac's efficacy, References Germany, Aug. 4, 1987. particularly with different oral dos 1. Cooper, S.A.Fivestudies on ibuprofen 9. Brown, C.R., Moodie, I.E., Evans, S.A., age regimens, before it can be rec tor postsurgical dental pain. Am I Med et al. Efficacy of intramuscular (I.M.) ke ommended for routine use in the 77(1A):70-77, 1984. torolac and meperidine in pain follow management of dental pain. 2. Cooper, S.A. The relative efficacy of ing major oral surgery, (abstr) Clin Phar Ketorolac is an example of how ibuprofen in dental pain. Compend macol Ther 43:161, 1988. vigorous marketing can make a Contin Educ Dent 7:579-597, 1986 more costly, but not necessarily su 3. lain. A.K., Ryan, J.R.,McMahon. F.G. perior analgesic, look more attrac et al. Analgesic efficacy of low-dose tive compared to what is already ibuprofen in dental extraction pain. available. It is much easier to cen Pharmacotherapy 6:318-322. 1986. tre our attention on a visually pleas 4. Forbes, ).A., Barkaszi, B.A., Ragland, ing product advertisement than on R.N. et al. Analgesic effect of fendosal, a dry scientific study. But as den ibuprofen and aspirin in postoperative tists, we have an obligation to our oral surgery pain. Pharmacotherapy patients to evaluate the advantages 4:385-391, 1984. of new therapies as they become 5. Mehlisch, D.R., Sollectio. W.A.. Hel- available. Indoing so, it is impera frick) |.F. etal. Muticenter clinical trial of tive that we base our judgements ibuprofen and acetaminophen in the treatment of postoperative dental pain. on the objective findings of prop jADA 121:257-263, 1990. erly performed scientific investiga tions rather than on subjective mar 6. Forbes, ).A., Butterwonh, G.A., Buch- field, W.H. et al. Evaluation of ketorolac, keting or a clinician's perception. aspirin and an acetaminophen-codeine New dental therapies should also combination in postoperative oral sur be judged on their cost effective gery pain. Pharmacotherapy10:77S-93. I.inu.iry/ 1990. l.invn-i ness to the patient. Otherwise, it 1994 would be a disservice to our pa 7. Forbes, j.A.. Kehm. C.J., Gordin. CD. Vol. dO No. I tients. • et al. Evaluation of ketorolac, ibuprofen, 32.
Load more

Recommended publications
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (See the end of this Medication Guide for a list of prescription NSAID medicines.) What is the most important information I should know about medicines called Non-Steroidal Anti- Inflammatory Drugs (NSAIDs)? NSAID medicines may increase the chance of a heart attack or stroke that can lead to death. This chance increases: • with longer use of NSAID medicines • in people who have heart disease NSAID medicines should never be used right before or after a heart surgery called a “coronary artery bypass graft (CABG).” NSAID medicines can cause ulcers and bleeding in the stomach and intestines at any time during treatment. Ulcers and bleeding: can happen without warning symptoms may cause death The chance of a person getting an ulcer or bleeding increases with: ▪ taking medicines called "corticosteroids” and “anticoagulants” ▪ longer use ▪ smoking ▪ drinking alcohol ▪ older age ▪ having poor health NSAID medicines should only be used: • exactly as prescribed • at the lowest dose possible for your treatment • for the shortest time needed What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? NSAID medicines are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as: different types of arthritis menstrual cramps and other types of short-term pain Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)? Do not take an NSAID medicine: • if you had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAID medicine • for pain right before or after heart bypass surgery Tell your healthcare provider: • about all of your medical conditions.
    [Show full text]
  • Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti- Inflammatory Drugs: a Systematic Review
    J Pharm Pharm Sci (www.cspsCanada.org) 21, 48s – 73s, 2018 Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti- Inflammatory Drugs: A Systematic Review Zuhair Alqahtani and Fakhreddin Jamali Faculty of Pharmacy and Pharmaceutical Science, University of Alberta, Edmonton, Alberta, Canada. Received, March 16, 2018; Revised, March 30, 2018; Accepted, April 25, 2018; Published, April 27, 2018. ABSTRACT - Purpose: Concomitant use of some non-Aspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) reduces the extent of platelet aggregation of Aspirin (acetylsalicylic acid). This is while many observational studies and clinical trials suggest that Aspirin reduces cardiovascular (CV) risk attributed to the use of NANSAIDs. Thus, the therapeutic outcome of the interaction needs to be assessed. Methods: We searched various databases up to October 2017 for molecular interaction studies between the drugs and long-term clinical outcomes based on randomized clinical trials and epidemiological observations that reported the effect estimates of CV risks (OR, RR or HR; 95% CI) of the interacting drugs alone or in combinations. Comparisons were made between outcomes after Aspirin alone, NANSAIDs alone and Aspirin with naproxen, ibuprofen, celecoxib, meloxicam, diclofenac or rofecoxib. Results: In total, 32 eligible studies (20 molecular interactions studies and 12 observational trials) were found. Conflicting in vitro/in vivo/ex vivo platelet aggregation data were found for ibuprofen, naproxen and celecoxib. Nevertheless, for naproxen, the interaction at the aggregation level did not amount to a loss of cardioprotective effects of Aspirin. Similarly, for ibuprofen, the results overwhelmingly suggest no negative clinical CV outcomes following the combination therapy. Meloxicam and rofecoxib neither interacted with Aspirin at the level of platelet aggregation nor altered clinical outcomes.
    [Show full text]
  • Ketorolac Tromethamine Injection
    ! • unusual weight gain Ketorolac Tromethamine Injection, USP Rx only Table 1: Table of Approximate Average Pharmacokinetic Parameters (Mean ± SD) IV-Administration: In normal subjects (n=37), the total clearance of 30 mg IV-administered ketorolac tromethamine was Anaphylactoid Reactions 0.030 (0.017-0.051) L/h/kg. The terminal half-life was 5.6 (4.0-7.9) hours. (See Kinetics in Special Populations for use of • skin rash or blisters with fever FOR IV/IM USE (15 mg/mL and 30 mg/mL) Following Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ketorolac tromethamine. Oral† Intramuscular* Intravenous Bolus‡ IV dosing of ketorolac tromethamine in pediatric patients.) Ketorolac tromethamine should not be given to patients with the aspirin triad. This symptom complex typically occurs in • swelling of the arms and legs, hands and feet FOR IM USE ONLY (60 mg/2 mL (30 mg/mL) asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm Pharmacokinetic CLINICAL STUDIES These are not all the side effects with NSAID medicines. Talk to your healthcare provider or Parameters 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS – Pre-existing Asthma). Emergency WARNING (units) Adult Patients help should be sought in cases where an anaphylactoid reaction occurs. pharmacist for more information about NSAID medicines. Bioavailability 100% In a postoperative study, where all patients received morphine by a PCA device, patients treated with ketorolac tromethamine IV Cardiovascular Effects Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days (extent) in adults) management of moderately severe acute pain that requires analgesia at the opioid level.
    [Show full text]
  • Patient Information Leaflet: Information for the User <Invented Name> 30
    Patient Information Leaflet: Information for the user <Invented name> 30 mg/ml solution for injection ketorolac trometamol Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What <Invented name> is and what it is used for 2. What you need to know before you are given <Invented name> 3. How <Invented name> is given 4. Possible side effects 5. How to store <Invented name> 6. Contents of the pack and other information 1. What <Invented name> is and what it is used for <Invented name> contains an active substance called ketorolac trometamol and belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Ketorolac is used in hospital, for short-term relief of moderate to severe pain after operations and in the case of acute kidney stone pain, in adults and adolescents ≥16 years. 2. What you need to know before you are given <Invented name> <Invented name> should not be used before or during surgery due to increased risk of bleeding. <Invented name> must not be given by epidural or intrathecal administration . Severe anaphylactic-like reactions have been observed in patients with a history of allergic reactions (symptoms of asthma, inflammation of the nasal mucosa or skin reactions) to the use of acetylsalicylic acid (e.g.
    [Show full text]
  • Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac Or Ketorolac
    molecules Article Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac Héctor Isaac Rocha-González 1 , María Elena Sánchez-Mendoza 1, Leticia Cruz-Antonio 2, Francisco Javier Flores-Murrieta 1,3, Xochilt Itzel Cornelio-Huerta 1 and Jesús Arrieta 1,* 1 Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Colonia Casco de Santo Tomás, Miguel Hidalgo, Ciudad de México 11340, Mexico; [email protected] (H.I.R.-G.); [email protected] (M.E.S.-M.); fjfl[email protected] (F.J.F.-M.); [email protected] (X.I.C.-H.) 2 Facultad de Estudios Superiores Zaragoza, UNAM, Av. Guelatao No. 66, Colonia Ejército de Oriente, Iztapalapa, Ciudad de México 09230, Mexico; [email protected] 3 Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosió Villegas, Secretaría de Salud, Ciudad de México 14080, Mexico * Correspondence: [email protected]; Tel.: +55-5729-6300 (ext. 62740); Fax: +55-5622-5329 Received: 13 October 2020; Accepted: 31 October 2020; Published: 3 November 2020 Abstract: Although nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the main types of drugs used to treat pain, they have several adverse effects, and such effects can be reduced by combining two analgesic drugs. The aim of this study was to evaluate the nociceptive activity of methyleugenol combined with either diclofenac or ketorolac, and determine certain parameters of pharmacokinetics. For the isobolographic analysis, the experimental effective dose 30 (ED30) was calculated for the drugs applied individually. With these effective doses, the peak plasma concentration (Cmax) was found and the other parameters of pharmacokinetics were established.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Myth: Parenteral Ketorolac Provides More Effective Analgesia Than Oral Ibuprofen
    EDUCATION • ÉDUCATION MEDICAL MYTHOLOGY Myth: Parenteral ketorolac provides more effective analgesia than oral ibuprofen Sanjay Arora, MD;* Jonathan G. Wagner, BA;† Mel Herbert, MD, MB BS, BMedSci‡ Introduction Results Acute pain is an extremely common presenting symptom to In 1994, Wright and associates evaluated the effectiveness the emergency department (ED), making it imperative that of a single dose of 800 mg of oral ibuprofen (n = 95) ver- emergency physicians provide adequate, safe and cost-ef- sus 60 mg of IM ketorolac (n = 70). This was a retrospec- fective analgesia. Nonsteroidal anti-inflammatory drugs tive analysis of data collected during a prior prospective (NSAIDs) are often first-line treatments for moderate to se- survey of pain management efficacy, in patients presenting vere pain. Physicians can choose between intramuscular to the ED with acute pain due to a large variety of causes.2 (IM) or intravenous (IV) ketorolac and an oral NSAID. The Using the 100-mm visual analog pain scale (VAS) they mechanism of action (reversible inhibition of prostaglandin found a mean score reduction of 34 in the ibuprofen group synthesis at the level of cyclooxygenase) is identical irre- and 35 in the ketorolac group. They concluded that the 2 spective of the route the medication is given.1 Despite the have almost identical efficacy in those presenting with similar pharmacodynamics, many physicians believe that acute pain of varied sources, and that unless oral adminis- parenteral ketorolac is more efficacious, despite a greater tration
    [Show full text]
  • Ketorolac Tromethamine Injection, USP
    PRODUCT MONOGRAPH Pr Ketorolac Tromethamine Injection, USP 30 mg / mL single-dose vials 30 mg / mL in SimplistTM prefilled single use syringes For Intramuscular Administration Non-Steroidal Anti-Inflammatory Analgesic Agent Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 July 18, 2019 Toronto, ON M9W 0C8 Submission Control No.: 227928 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ................................................................................3 INDICATIONS AND CLINICAL USE .....................................................................................3 CONTRAINDICATIONS ...........................................................................................................4 WARNINGS AND PRECAUTIONS .........................................................................................5 ADVERSE REACTIONS .........................................................................................................14 DRUG INTERACTIONS..........................................................................................................16 DOSAGE AND ADMINISTRATION .....................................................................................18 OVERDOSAGE ........................................................................................................................22 ACTION AND CLINICAL PHARMACOLOGY ....................................................................23 STORAGE
    [Show full text]
  • Perioperative Use of Nsaids: Safety and Guidelines
    CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS Perioperative Use of NSAIDs: Safety and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: April 5, 2018 Report Length: 19 Pages Authors: Casey Gray, Charlene Argaez Cite As: Perioperativ e use of NSAIDs: saf ety and guidelines. Ottawa: CADTH; 2018 Apr. (CADTH rapid response report: summary of abstracts). Acknowledgments: Disclaimer: The inf ormation in this document is intended to help Canadian health care decision-makers, health care prof essionals, health sy stems leaders, and policy -makers make well-inf ormed decisions and thereby improv e the quality of health care serv ices. While patients and others may access this document, the document is made av ailable f or inf ormational purposes only and no representations or warranties are made with respect to its f itness f or any particular purpose. The inf ormation in this document should not be used as a substitute f or prof essional medical adv ice or as a substitute f or the application of clinical judgment in respect of the care of a particular patient or other prof essional judgment in any decision-making process. The Canadian Agency f or Drugs and Technologies in Health (CADTH) does not endorse any inf ormation, drugs, therapies, treatments, products, processes, or serv ic es. While care has been taken to ensure that the inf ormation prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was f irst published by CADTH, CADTH does not make any guarantees to that ef f ect.
    [Show full text]
  • (Toradol) Tablet Utilization Management Criteria
    KETOROLAC (TORADOL) TABLET UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Non-steroidal anti-inflammatory drugs (NSAIDs) HICL = 00000000005175 BRAND NAME: Toradol 10 mg oral tablets (Generic): (ketorolac tromethamine) FDA INDICATIONS: Toradol is indicated for the short-term (5 days or less) management of moderately severe acute pain that requires analgesia at the opioid level. It is NOT indicated for minor or chronic painful conditions. ICD-9 CODE: Various codes may apply; any ICD-9 code that states acute pain from any origin is acceptable. QUANTITY LIMITATIONS (QL) CRITERIA: • QL: (short-term only, not appropriate for extended-supply) Toradol 20 tablets/5 day supply within 30 day period (or 200 mg/30 days) • If patient requires additional medication, please follow the criteria developed for Toradol. RATIONALE: Quantity limitations are based on restrictions placed by the FDA in the package inserts for Toradol: • Toradol tablets are only indicated as follow up to Toradol injection: Combined use beyond 5 days increases the risk of serious adverse effects such as peptic ulcer and gastrointestinal bleeding/perforation. The maximum number of tablets per prescription should be 20 or less due to the fact that combined usage of injection and oral should not exceed 5 days. CRITERIA FOR EXCEEDING QL: 1. Convey to physician the amount of the drug that the patient has already received (refer to QL) and ask if the patient needs more than that amount AND 2. Toradol tablets are only indicated as follow up to Toradol injection AND 3. Patient must have the diagnosis of moderate to severe acute pain (not chronic, osteoarthritis or rheumatoid arthritis) AND 4.
    [Show full text]
  • Ketorolac Tromethamine Injection Usp
    PRODUCT MONOGRAPH PrKETOROLAC TROMETHAMINE INJECTION USP (Ketorolac Tromethamine) Sterile Solution 30 mg/mL Non-Steroidal Anti-Inflammatory Drug (NSAID) Pfizer Canada Inc. Date of Revision: 17300 Trans-Canada Highway December 1, 2017 Kirkland, Québec H9J 2M5 Submission Control No: 209949 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................14 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION ..............................................................................19 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]